Filana Therapeutics Inc. (FLNA:NASDAQ) closed at $0.636 on October 23, 2026, down 2.84% on the day. The stock trades 84.2% below its 52-week high of $4.01 and 3.2% above its 52-week low of $0.616. Over the past year, it lost 83.2%. Filana Therapeutics Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, FLNA closed higher on 99 days (39%). Its best day was September 22, 2026 (+39.19%) and its worst was December 19, 2025 (-23.51%). The stock moved 10% or more in a single session 11 times. It opened at least 5% above the previous day's high 3 times.
Cassava Sciences, Inc. (NASDAQ: SAVA), is a biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications. Simufilam is a proprietary, investigational oral small molecule believed to modulate activity of the filamin A protein, which regulates diverse aspects of neuronal development1. The Company is planning a Phase 2 proof-of-concept study to evaluate simufilam in patients with TSC-related epilepsy, collaborating closely with the TSC Alliance and key opinion leaders. The program is based on a method of treatment patent issued in 2025 and in-licensed from Yale University. Cassava is based in Austin, Texas.
Find more stocks like FLNA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.